Last update Oct. 21, 2024

سيماغلوتيد

Compatible

Safe product and/or breastfeeding is the best option.

Semaglutide is an incretin hormone analog used in the treatment of type 2 diabetes and for weight control in adults with obesity (BMI > 30) or overweight with associated morbidity. Administration of a weekly dose subcutaneously.

Its high molecular weight, very high binding to plasma proteins and moderately high volume of distribution explain the null excretion found in breast milk in women treated with doses of up to 1 mg weekly. No clinical problems were observed in infants breast-fed by these mothers. (Diab 2024)

In addition, due to its protein nature it is inactivated in the gastrointestinal tract, not being absorbed, (oral bioavailability practically null, < 1%), which hinders or prevents the passage to infant plasma from ingested breast milk (Serrano 2015), except in premature infants and immediate neonatal period, in which there may be greater intestinal permeability.

Diet, exercise and breastfeeding improve blood glucose levels.


See below the information of this related product:

  • Maternal Diabetes mellitus (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

سيماغلوتيد is Semaglutide in Arabic.

Is written in other languages:

Groups

سيماغلوتيد belongs to these groups or families:

Tradenames

Main tradenames from several countries containing سيماغلوتيد in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0.4 - 1 %
Molecular weight 4.114 daltons
Protein Binding 99 %
VD 0.18 l/Kg
pKa 2.74 -
Tmax 72 hours
T½ 168 hours
Theoretical Dose < 0.00026 mg/Kg/d
Relative Dose 0 ( < 1%) %

References

  1. Diab H, Fuquay T, Datta P, Bickel U, Thompson J, Krutsch K. Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk. Nutrients. 2024 Aug 28;16(17). Abstract Full text (link to original source)
  2. FDA. Semaglutide. Drug Summary. 2020 Full text (in our servers)
  3. AEMPS. Semaglutida. Ficha técnica. 2018 Full text (in our servers)
  4. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract

Total visits

1,182

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM